KR100788241B1 - 백반증의 예방 또는 치료물질을 스크리닝하는 방법 - Google Patents
백반증의 예방 또는 치료물질을 스크리닝하는 방법 Download PDFInfo
- Publication number
- KR100788241B1 KR100788241B1 KR1020070006652A KR20070006652A KR100788241B1 KR 100788241 B1 KR100788241 B1 KR 100788241B1 KR 1020070006652 A KR1020070006652 A KR 1020070006652A KR 20070006652 A KR20070006652 A KR 20070006652A KR 100788241 B1 KR100788241 B1 KR 100788241B1
- Authority
- KR
- South Korea
- Prior art keywords
- tnf
- vitiligo
- akt
- cells
- epidermis
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (2)
- 다음의 단계를 포함하는 백반증의 예방 또는 치료 물질을 스크리닝하는 방법:(a) 백반증의 표피세포를 분리하여 이를 배양하는 단계;(b) 상기 배양된 표피세포에 백반증 예방 또는 치료제 후보물질을 접촉시키는 단계;(c) 상기 후보물질 접촉된 세포에서 I-κB, NF-κB, Akt 또는 IKK의 인산화를 측정하는 단계; 및(d) 상기 I-κB, NF-κB, Akt 또는 IKK의 인산화를 증가시키는 후보물질을 선별하는 단계.
- 제1항에 있어서, 상기 백반증의 표피세포는 각질형성세포인 것을 특징으로 하는 백반증의 예방 또는 치료제를 스크리닝하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070006652A KR100788241B1 (ko) | 2007-01-22 | 2007-01-22 | 백반증의 예방 또는 치료물질을 스크리닝하는 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070006652A KR100788241B1 (ko) | 2007-01-22 | 2007-01-22 | 백반증의 예방 또는 치료물질을 스크리닝하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100788241B1 true KR100788241B1 (ko) | 2007-12-27 |
Family
ID=39147875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070006652A KR100788241B1 (ko) | 2007-01-22 | 2007-01-22 | 백반증의 예방 또는 치료물질을 스크리닝하는 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100788241B1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100951446B1 (ko) | 2009-01-23 | 2010-04-07 | 동국대학교 산학협력단 | 백반증 진단용 tslp 다형성 마커 |
KR101146597B1 (ko) * | 2010-03-16 | 2012-05-16 | 동국대학교 산학협력단 | 백반증 진단용 조성물 |
KR20200037905A (ko) | 2018-10-01 | 2020-04-10 | 동국대학교 산학협력단 | Ofd1을 이용한 피부 탈색 질환 치료용 조성물의 스크리닝 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050076690A (ko) * | 2004-01-20 | 2005-07-26 | 학교법인 을지학원 | 백반증의 치료 또는 예방에 유효한 약물에 대한 반응성을스크리닝하는 방법 및 백반증의 예후 판정방법 |
KR20060091829A (ko) * | 2005-02-15 | 2006-08-22 | (주)한국스티펠 | 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물 |
-
2007
- 2007-01-22 KR KR1020070006652A patent/KR100788241B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050076690A (ko) * | 2004-01-20 | 2005-07-26 | 학교법인 을지학원 | 백반증의 치료 또는 예방에 유효한 약물에 대한 반응성을스크리닝하는 방법 및 백반증의 예후 판정방법 |
KR20060091829A (ko) * | 2005-02-15 | 2006-08-22 | (주)한국스티펠 | 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물 |
Non-Patent Citations (5)
Title |
---|
Am. J. Physiol. Gastrointest. Liver Physiol., 282, G1357-1368(2002) |
J. Investigative Dermatology, 117(4), 898-907(2001) |
대한민국공개특허 제10-2005-0076690호(2005.07.26.) |
대한민국공개특허 제10-2006-0091829호(2006.08.22.) |
미국공개특허 제2004/0229785호(2004.11.18.) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100951446B1 (ko) | 2009-01-23 | 2010-04-07 | 동국대학교 산학협력단 | 백반증 진단용 tslp 다형성 마커 |
KR101146597B1 (ko) * | 2010-03-16 | 2012-05-16 | 동국대학교 산학협력단 | 백반증 진단용 조성물 |
KR20200037905A (ko) | 2018-10-01 | 2020-04-10 | 동국대학교 산학협력단 | Ofd1을 이용한 피부 탈색 질환 치료용 조성물의 스크리닝 방법 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leask et al. | Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts | |
González-Ramos et al. | Agents blocking the nuclear factor-κB pathway are effective inhibitors of endometriosis in an in vivo experimental model | |
Lan et al. | Bisphenol A exposure promotes HTR-8/SVneo cell migration and impairs mouse placentation involving upregulation of integrin-β1 and MMP-9 and stimulation of MAPK and PI3K signaling pathways | |
Zhang et al. | Silencing H19 regulated proliferation, invasion, and autophagy in the placenta by targeting miR‐18a‐5p | |
Kikuchi et al. | GCN5 and BCR signalling collaborate to induce pre-mature B cell apoptosis through depletion of ICAD and IAP2 and activation of caspase activities | |
Ahuja et al. | Association of cyclin‐dependent kinase 5 and its activator p35 with apoptotic cell death | |
Gao et al. | Mi RNA‐320a inhibits trophoblast cell invasion by targeting estrogen‐related receptor‐gamma | |
Qiu et al. | Expression and clinical role of Cdc5L as a novel cell cycle protein in hepatocellular carcinoma | |
US20070049539A1 (en) | Rsk inhibitors and therapeutic uses thereof | |
KR100788241B1 (ko) | 백반증의 예방 또는 치료물질을 스크리닝하는 방법 | |
Izawa et al. | GATA6 expression promoted by an active enhancer may become a molecular marker in endometriosis lesions | |
Jiang et al. | Stimulation of prostate cells by the senescence phenotype of epithelial and stromal cells: Implication for benign prostate hyperplasia | |
Zhang et al. | Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism | |
Li et al. | Endometrial stromal cells treated by tumor necrosis factor‐α stimulate macrophages polarized toward M2 via interleukin‐6 and monocyte chemoattractant protein‐1 | |
EP1301794B1 (en) | Method for quantification of akt protein expression | |
Lin et al. | Up-regulation of Orai1 in murine allergic rhinitis | |
Clemens et al. | Ethanol metabolism results in a G2/M cell-cycle arrest in recombinant Hep G2 cells | |
Partik et al. | Apoptosis in human colorectal tumours: ultrastructure and quantitative studies on tissue localization and association with bak expression | |
Liu et al. | Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells | |
Mayer et al. | Immunohistochemical evaluation of cathepsin D expression in colorectal cancer | |
EP0828854B1 (en) | Analytical and therapeutic agents | |
Batwa et al. | Prevalence of cytomegalovirus, and its effect on the expression of inducible and endothelial nitric oxide synthases in Fallopian tubes collected from women with and without ectopic pregnancy | |
Karamitopoulou et al. | Active caspase 3 and DNA fragmentation as markers for apoptotic cell death in primary and metastatic liver tumours | |
Cataldi et al. | Phosphatidylinositol-3-kinase activation and atypical protein kinase C ζ phosphorylation characterize the DMSO signalling in erythroleukemia cells | |
Jiang et al. | Endometrial cell‑derived exosomes facilitate the development of adenomyosis via the IL‑6/JAK2/STAT3 pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121218 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131217 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141121 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151113 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161206 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181010 Year of fee payment: 12 |